NCT01703559View on ClinicalTrials.gov

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 9, 2011

Primary Completion Date

April 16, 2012

Study Completion Date

April 30, 2012

Conditions
Night Vision ComplaintsDecrease in Night VisionDisturbance; Vision, Loss
Interventions
DRUG

Phentolamine Mesylate Ophthalmic Solution 1.0%

Phentolamine mesylate (Nyxol) ophthalmic solution 1.0% is a non-selective alpha-1 and alpha-2 adrenergic antagonist

DRUG

Phentolamine Mesylate Ophthalmic Solution 0.5%

Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist

OTHER

Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)

Placebo (vehicle) is a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate

Trial Locations (1)

67230

Celerion, Phoenix

Sponsors
All Listed Sponsors
lead

Ocuphire Pharma, Inc.

INDUSTRY

NCT01703559 - The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances | Biotech Hunter | Biotech Hunter